Two integrases inhibitors, raltegravir and elvitegravir, have now been approved by regulatory agencies for use in the treatment of HIV-infected patients; and the approval of a third such drug, dolutegravir, is expected during 2013 on the basis of several phase 3 clinical trials. The advent of this new class of antiretroviral (ARV) medications represents a major advance in the management of HIV infection, and each of these three drugs can be expected to continue to be an important component of ARV combination regimens. © 2012 Raffi and Wainberg; licensee BioMed Central Ltd.
CITATION STYLE
Raffi, F., & Wainberg, M. A. (2012). Multiple choices for HIV therapy with integrase strand transfer inhibitors. Retrovirology, 9. https://doi.org/10.1186/1742-4690-9-110
Mendeley helps you to discover research relevant for your work.